A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.
Bizcommunity on MSN1d
When it’s not flu…While the ‘official’ flu season may still be a month or two away, reports indicate a rise in respiratory illnesses like the ...
Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform ...
Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...
The respiratory syncytial virus (RSV) infects cells along the human respiratory tract, from the nose to the lungs. Each year ...
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
The Triad's three main healthcare systems separately announced Wednesday they will lift at 7 a.m. Thursday their respiratory ...
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...
A panel of CDC advisers, who had been set to meet in February, will discuss the current measles outbreak as well as ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback